Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Touyun Biotech Group stock price, quote, forecast and news

1332.HK
BMG8962M1038

Price

0.17 HKD
Today +/-
+0 HKD
Today %
+0 %
P

Touyun Biotech Group stock price

HKD
%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Touyun Biotech Group stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Touyun Biotech Group stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Touyun Biotech Group stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Touyun Biotech Group's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Touyun Biotech Group Stock Price History

DateTouyun Biotech Group Price
9/25/20240.17 HKD
9/24/20240.17 HKD
9/23/20240.17 HKD
9/20/20240.17 HKD
9/19/20240.18 HKD
9/17/20240.18 HKD
9/16/20240.18 HKD
9/13/20240.18 HKD
9/12/20240.18 HKD
9/11/20240.17 HKD
9/10/20240.17 HKD
9/9/20240.17 HKD
9/5/20240.17 HKD
9/4/20240.17 HKD
9/3/20240.17 HKD
9/2/20240.17 HKD
8/30/20240.17 HKD
8/29/20240.17 HKD
8/28/20240.17 HKD

Touyun Biotech Group Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Touyun Biotech Group, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Touyun Biotech Group from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Touyun Biotech Group’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Touyun Biotech Group. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Touyun Biotech Group’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Touyun Biotech Group’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Touyun Biotech Group’s growth potential.

Touyun Biotech Group Revenue, EBIT and net profit per share

DateTouyun Biotech Group RevenueTouyun Biotech Group EBITTouyun Biotech Group Net Income
2023198.64 M HKD-85.85 M HKD-268.94 M HKD
2022315.83 M HKD-38.3 M HKD-198.07 M HKD
2021283.51 M HKD-28.07 M HKD-72.95 M HKD
2020206.79 M HKD-58.07 M HKD-168.78 M HKD
2019342.7 M HKD-32.12 M HKD-200.51 M HKD
2018348.77 M HKD-130.83 M HKD-253.88 M HKD
2017317.7 M HKD-134.02 M HKD-245.23 M HKD
2016-37.62 M HKD-367.74 M HKD-1.15 B HKD
2015285.97 M HKD-104.91 M HKD255.26 M HKD
2014397.04 M HKD13.22 M HKD10.35 M HKD
2013436.4 M HKD18.8 M HKD13.4 M HKD
2012389.3 M HKD25.8 M HKD20.3 M HKD
2011418.7 M HKD44.8 M HKD37.8 M HKD
2010391.1 M HKD36.1 M HKD27.4 M HKD
2009294.7 M HKD22.2 M HKD16.4 M HKD

Touyun Biotech Group Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M HKD)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M HKD)EBIT (M HKD)EBIT MARGIN (%)NET INCOME (M HKD)NET INCOME GROWTH (%)SHARES (B)DOCUMENTS
200920102011201220132014201520162017201820192020202120222023
294391418389436397285-37317348342206283315198
-32.996.91-6.9412.08-8.94-28.21-112.98-956.769.78-1.72-39.7737.3811.31-37.14
19.0519.1820.3318.2515.8316.621.75740.5411.6727.0136.5540.7837.8138.1028.28
5675857169665-27437941258410712056
223644251813-104-367-134-130-32-58-28-38-85
7.489.2110.536.434.133.27-36.49991.89-42.27-37.36-9.36-28.16-9.89-12.06-42.93
162737201310255-1,150-245-253-200-168-72-198-268
-68.7537.04-45.95-35.00-23.082,450.00-550.98-78.703.27-20.95-16.00-57.14175.0035.35
0.90.90.90.850.90.90.911.632.452.452.452.672.792.812.81
---------------
Details

Keystats

ⓘ

Revenue and Growth

The Touyun Biotech Group Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Touyun Biotech Group is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M HKD)RECEIVABLES (M HKD)OTHER REC. (M HKD)INVENTORIES (M HKD)OTHER CURRENT LIAB. (M HKD)CURRENT ASSETS (M HKD)TANGIBLE ASSETS (M HKD)LONG-T. INVEST. (M HKD)LONG-T. REC. (k HKD)INTANGIBLE ASSETS (M HKD)GOODWILL (M HKD)OTHER NON-CURRENT ASSETS (M HKD)NON-CURRENT ASSETS (M HKD)TOTAL ASSETS (B HKD)LIABILITIESCOMMON STOCK (M HKD)ADDITIONAL PAID-IN CAPITAL (B HKD)RETAINED EARNINGS (M HKD)OTHER EQUITY (M HKD)UNREAL. GAINS/LOSSES (M HKD)EQUITY (B HKD)LIABILITIES (M HKD)PROVISIONS (M HKD)OTHER SHORT-TERM LIAB. (M HKD)SHORT-TERM DEBTS (M HKD)LONG-TERM DEBT PORTION (M HKD)SHORT-TERM REC. (M HKD)LONG-T. LIAB. (M HKD)DEFERRED TAXES (M HKD)OTHER LIAB. (M HKD)LONG-T. LIABILITIES (M HKD)DEBT (M HKD)TOTAL CAPITAL (B HKD)
200920102011201220132014201520162017201820192020202120222023
                             
55.365.359.881.580.5303.550303.55362.91121.76199.28254.493.95144.2536.04
38.252.845.951.653.364.79064.7975.2561.854.7658.6966.2941.4527.14
1.11.40.210.63.5503.559.31193.2473.3111.9766.1890.5169.83
34.943.13936.141.620.93020.9322.5535.629.5733.7432.7735.6115.25
2.62.94.95.211.68.7108.7128.6522.277.859.729.0310.1814.23
132.1165.5149.8175.4187.6401.530401.53498.66434.67364.76468.51268.22322.01162.48
135.2131.3124.8121.2119.527.98027.9870.6736.4252.69172.2435.95381.28310.63
1.71.10.61.11.1566.220566.22552.79391.85458.21320.69318.94184.13134.03
00000000000000199
000002.5202.5215.8116.0510.7410.041.620.280
00000266.510266.51201.73164.700.51000
14.514.113.713.312.92.202.28.77000000
151.4146.5139.1135.6133.5865.420865.42849.77609.03521.64503.43756.51565.69444.86
0.280.310.290.310.321.2701.271.351.040.890.971.020.890.61
                             
00014.414.497.97097.9797.9797.9797.97110.95112.24112.24112.24
0000.020.020.2401.771.771.771.771.881.911.911.91
98.4125.8164214.6228-678.740-678.74-914-1,145.83-1,332.02-1,514.93-1,571.07-1,762.28-2,028.64
00000.114.560-3.743.945.225.8215.7321.096.357.89
000001.523.4100000000
0.10.130.160.250.26-0.3201.180.960.730.540.490.470.26-0
155.314790.731.731.925.57025.5747.842.1232.1529.9737.8846.2217.96
12.212.411.613.411.29.31024.7215.3915.2913.1513.8912.1515.4916.91
14.423.519.115.314.311.06011.0626.4139.5435.63149.09168.88147.46166.49
00000201.05012.020011.688.05296.2400
000000001.54219.46239.17126.4814.41200.82179.36
181.9182.9121.460.457.4246.98073.3691.12316.41331.7407.48529.56410380.71
00000000299.36010.148.098.12194.19205.55
1.11.111.51.50.1700.170.060.0400000
000000000000000
1.11.111.51.50.1700.17299.420.0410.148.098.12194.19205.55
183184122.461.958.9247.16073.53390.54316.46341.83415.57537.68604.19586.27
0.280.310.290.310.32-0.0701.261.351.040.880.91.010.870.59
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Touyun Biotech Group provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Touyun Biotech Group's financial health and stability.

Assets

Touyun Biotech Group's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Touyun Biotech Group must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Touyun Biotech Group after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Touyun Biotech Group's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M HKD)DEPRECIATION (M HKD)DEFERRED TAXES (M HKD)CHANGES IN WORKING CAPITAL (M HKD)NON-CASH ITEM (B HKD)PAID INTEREST (M HKD)PAID TAXES (M HKD)NET CASH FLOW FROM OPERATING ACTIVITIES (M HKD)CAPITAL EXPENDITURES (M HKD)CASH FLOW FROM INVESTING ACTIVITIES (M HKD)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M HKD)INTEREST INCOME AND EXPENSES (M HKD)NET DEBT CHANGE (M HKD)NET CHANGE IN EQUITY (M HKD)CASH FLOW FROM FINANCING ACTIVITIES (M HKD)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M HKD)TOTAL DIVIDENDS PAID (M HKD)NET CHANGE IN CASH FLOW (M HKD)FREE CASH FLOW (M HKD)SHARE-BASED COMPENSATION (M HKD)
20092010201120122013201420152016201720182019202020212022
213546261913256-1,163-248-251-194-171-122-199
6655542392831282233
00000000000000
23-6-5-16-117-470258-2-21-2110-57-39
00-0000-0.251.130.20.130.170.130.10.18
00000001001816373118
23541210017-231
533745151328-458225-40-117-204-15-53-26
0-20-1-300-6-51-36-7-125-250-12
-2-20-8-3-7168-242-117-28155-47-147-17
-100-70-7169-235-65716377103-4
00000000000000
000000201-189299-108-8-719181
0002200191618000030
-77-24-517-40389186296-108-7160123102
-77-24-51-15-40-2-242-2012322920
00000000000000
-2510-5146-430169142-251-57101-8267
53.234.74514.210.627.86-459.15219.59-92.9-153.33-212.59-140.86-304.6-39.3
00000000000000

Touyun Biotech Group stock margins

The Touyun Biotech Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Touyun Biotech Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Touyun Biotech Group.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Touyun Biotech Group's sales revenue. A higher gross margin percentage indicates that the Touyun Biotech Group retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Touyun Biotech Group's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Touyun Biotech Group's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Touyun Biotech Group's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Touyun Biotech Group. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Touyun Biotech Group's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Touyun Biotech Group Margin History

Touyun Biotech Group Gross marginTouyun Biotech Group Profit marginTouyun Biotech Group EBIT marginTouyun Biotech Group Profit margin
202328.5 %-43.22 %-135.39 %
202238.03 %-12.13 %-62.71 %
202137.76 %-9.9 %-25.73 %
202040.92 %-28.08 %-81.62 %
201936.62 %-9.37 %-58.51 %
201827.15 %-37.51 %-72.79 %
201711.89 %-42.18 %-77.19 %
2016728.49 %977.43 %3,058.83 %
20151.83 %-36.69 %89.26 %
201416.69 %3.33 %2.61 %
201315.93 %4.31 %3.07 %
201218.29 %6.63 %5.21 %
201120.52 %10.7 %9.03 %
201019.25 %9.23 %7.01 %
200919.27 %7.53 %5.56 %

Touyun Biotech Group Stock Sales Revenue, EBIT, Earnings per Share

The Touyun Biotech Group earnings per share therefore indicates how much revenue Touyun Biotech Group has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Touyun Biotech Group earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Touyun Biotech Group's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Touyun Biotech Group’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Touyun Biotech Group's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Touyun Biotech Group Revenue, EBIT and net profit per share

DateTouyun Biotech Group Sales per ShareTouyun Biotech Group EBIT per shareTouyun Biotech Group Earnings per Share
20230.07 HKD-0.03 HKD-0.1 HKD
20220.11 HKD-0.01 HKD-0.07 HKD
20210.1 HKD-0.01 HKD-0.03 HKD
20200.08 HKD-0.02 HKD-0.06 HKD
20190.14 HKD-0.01 HKD-0.08 HKD
20180.14 HKD-0.05 HKD-0.1 HKD
20170.13 HKD-0.05 HKD-0.1 HKD
2016-0.02 HKD-0.23 HKD-0.71 HKD
20150.31 HKD-0.11 HKD0.28 HKD
20140.44 HKD0.01 HKD0.01 HKD
20130.49 HKD0.02 HKD0.01 HKD
20120.46 HKD0.03 HKD0.02 HKD
20110.47 HKD0.05 HKD0.04 HKD
20100.44 HKD0.04 HKD0.03 HKD
20090.33 HKD0.02 HKD0.02 HKD

Touyun Biotech Group business model

Touyun Biotech Group is one of the most popular companies on Eulerpool.com.

Touyun Biotech Group Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Touyun Biotech Group historical P/E ratio, EBIT, and P/S ratio.

Touyun Biotech Group shares outstanding

The number of shares was Touyun Biotech Group in 2023 — This indicates how many shares 2.806 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Touyun Biotech Group earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Touyun Biotech Group's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Touyun Biotech Group’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Touyun Biotech Group's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Touyun Biotech Group Stock splits

In Touyun Biotech Group's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Touyun Biotech Group.

Touyun Biotech Group list of shareholders

%
Name
Stocks
Change
Date
7.03755 % Qin (Fen)197,470,000012/31/2022
5.34578 % TY Technology Group Ltd.150,000,000012/31/2022
5.21945 % Tian (Yuze)146,455,135-1,050,00012/12/2023
22.00681 % Wang (Liang)617,500,000-5,000,00012/15/2023
0.03564 % Jia (Wenjie)1,000,000012/31/2022
0 % DBX Advisors LLC.0-180,1361/31/2024
1

Touyun Biotech Group Executives and Management Board

Mr. Liang Wang36
Touyun Biotech Group Executive Chairman of the Board (since 2016)
Compensation 3.92 M HKD
Mr. Dong Du36
Touyun Biotech Group Executive Director (since 2016)
Compensation 1.46 M HKD
Mr. Wing Ping Cheung55
Touyun Biotech Group Independent Non-Executive Director
Compensation 258,000 HKD
Mr. Kee Choy Ha65
Touyun Biotech Group Independent Non-Executive Director
Compensation 258,000 HKD
Mr. Shing Chuen To71
Touyun Biotech Group Independent Non-Executive Director
Compensation 258,000 HKD
1
2
3

Touyun Biotech Group Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Arta TechFin Stock
Arta TechFin
SupplierCustomer0,140,54-0,130,73--
1

Most common questions regarding Touyun Biotech Group

What is the P/E ratio of Touyun Biotech Group 2024?

The P/E ratio cannot be calculated for Touyun Biotech Group at the moment.

What is the P/S ratio of Touyun Biotech Group 2024?

The P/S cannot be calculated for Touyun Biotech Group currently.

What is the AlleAktien quality score of Touyun Biotech Group?

The AlleAktien quality score for Touyun Biotech Group is 3/10.

What is the revenue of Touyun Biotech Group 2024?

The revenue cannot currently be calculated for Touyun Biotech Group.

How high is the profit of Touyun Biotech Group 2024?

The profit cannot currently be calculated for Touyun Biotech Group.

What is the business model of Touyun Biotech Group

No history available for Touyun Biotech Group.

What is the Touyun Biotech Group dividend?

Touyun Biotech Group pays a dividend of 0 HKD distributed over payouts per year.

How often does Touyun Biotech Group pay dividends?

The dividend cannot currently be calculated for Touyun Biotech Group or the company does not pay out a dividend.

What is the Touyun Biotech Group ISIN?

The ISIN of Touyun Biotech Group is BMG8962M1038.

What is the Touyun Biotech Group ticker?

The ticker of Touyun Biotech Group is 1332.HK.

How much dividend does Touyun Biotech Group pay?

Over the past 12 months, Touyun Biotech Group paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Touyun Biotech Group is expected to pay a dividend of 0 HKD.

What is the dividend yield of Touyun Biotech Group?

The current dividend yield of Touyun Biotech Group is .

When does Touyun Biotech Group pay dividends?

Touyun Biotech Group pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Touyun Biotech Group?

Touyun Biotech Group paid dividends every year for the past 0 years.

What is the dividend of Touyun Biotech Group?

For the upcoming 12 months, dividends amounting to 0 HKD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Touyun Biotech Group located?

Touyun Biotech Group is assigned to the 'Commodities' sector.

Wann musste ich die Aktien von Touyun Biotech Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Touyun Biotech Group from 9/26/2024 amounting to 0 HKD, you needed to have the stock in your portfolio before the ex-date on 9/26/2024.

When did Touyun Biotech Group pay the last dividend?

The last dividend was paid out on 9/26/2024.

What was the dividend of Touyun Biotech Group in the year 2023?

In the year 2023, Touyun Biotech Group distributed 0 HKD as dividends.

In which currency does Touyun Biotech Group pay out the dividend?

The dividends of Touyun Biotech Group are distributed in HKD.

All fundamentals about Touyun Biotech Group

Our stock analysis for Touyun Biotech Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Touyun Biotech Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.